1. Ahlgren C, Odén A, Lycke J. High nationwide prevalence of multiple Sclerosis in Sweden. Mult Scler J. 2011; 17(8):901-8.[DOI:10.1177/1352458511403794] [PMID] [
DOI:10.1177/1352458511403794]
2. Milo R, Kahana E. Multiple Sclerosis: Geoepidemiology, genetics and the environment. Autoimmun Rev. 2010; 9(5):A387-94. [DOI:10.1016/j.autrev.2009.11.010] [PMID] [
DOI:10.1016/j.autrev.2009.11.010]
3. Peterson LK, Fujinami RS. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple Sclerosis. J Neuroimmunol. 2007; 184(1-2):37-44. [DOI:10.1016/j.jneuroim.2006.11.015] [PMID] [PMCID] [
DOI:10.1016/j.jneuroim.2006.11.015]
4. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple Sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69(2):292-302. [DOI:10.1002/ana.22366] [PMID] [PMCID] [
DOI:10.1002/ana.22366]
5. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple Sclerosis: Guidelines from the International Panel on the diagnosis of Multiple Sclerosis. Ann Neurol. 2001; 50(1):121-27. [DOI:10.1002/ana.1032] [PMID] [
DOI:10.1002/ana.1032]
6. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple Sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005; 58(6):840-6. [DOI:10.1002/ana.20703] [PMID] [
DOI:10.1002/ana.20703]
7. De Groot L, Posthumus MD, Kallenberg CG, Bijl M. Risk factors and early detection of atherosclerosis in rheumatoid arthritis. Eur J Clin Invest. 2010; 40(9):835-42. [DOI:10.1111/j.1365-2362.2010.02333.x] [PMID] [
DOI:10.1111/j.1365-2362.2010.02333.x]
8. Kramer HR, Giles JT. Cardiovascular disease risk in rheumatoid arthritis: progress, debate, and opportunity. Arthritis Care Res. 2011; 63(4):484-99. [DOI:10.1002/acr.20386] [PMID] [
DOI:10.1002/acr.20386]
9. Patel RV, Shelling ML, Prodanovich S, Federman DG, Kirsner RS. Psoriasis and vascular disease-risk factors and outcomes: A systematic review of the literature. Arthritis Care Res. 2011; 26(9):1036-49. [DOI:10.1007/s11606-011-1698-5] [PMID] [PMCID] [
DOI:10.1007/s11606-011-1698-5]
10. De Simone C, Di Giorgio A, Sisto T, Carbone A, Ghitti F, Tondi P, et al. Endothelial dysfunction in psoriasis patients: Cross-sectional case-control study. Eur J Dermatol. 2011; 21(4):510-4. [PMID] [
PMID]
11. Huck O, Saadi Thiers K, Tenenbaum H, Davideau JL, Romagna C, Laurent Y, et al. Evaluating periodontal risk for patients at risk of or suffering from atherosclerosis: Recent biological hypotheses and therapeutic consequences. Arch Cardiovasc Dis. 2011; 104(5):352-8. [DOI:10.1016/j.acvd.2011.02.002] [PMID] [
DOI:10.1016/j.acvd.2011.02.002]
12. Beukers NG, Van Der Heijden GJ, Van Wijk AJ, Loos BG. Periodontitis is an independent risk indicator for atherosclerotic cardiovascular diseases among 60 174 participants in a large dental school in the Netherlands. BMJ. 2017; 71; 37-42.
13. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340(2):115-26. [DOI:10.1056/NEJM199901143400207] [PMID] [
DOI:10.1056/NEJM199901143400207]
14. Weill C, Suissa L, Darcourt J, Mahagne MH. The pathophysiology of watershed infarction: A three-dimensional time-of-flight magnetic resonance angiography study. J Stroke Cerebrovasc Dis. 2017; 26(9):1966-73. [DOI:10.1016/j.jstrokecerebrovasdis.2017.06.016] [PMID] [
DOI:10.1016/j.jstrokecerebrovasdis.2017.06.016]
15. Maki T, Wakita H, Mase M, Itagaki I, Saito N, Ono F, et al. Watershed infarcts in a multiple microembolic model of monkey. Neurosci Lett. 2011; 499(2):80-3. [DOI:10.1016/j.neulet.2011.05.036] [PMID] [
DOI:10.1016/j.neulet.2011.05.036]
16. Rosso C, Remy P, Creange A, Brugieres P, Cesaro P, Hosseini H. Diffusion-weighted MR imaging characteristics of acute stroke like form of multiple Sclerosis. AJNR Am J Neuroradiol. 2006; 27(5):1006-8. [PMID] [
PMID]
17. Jadidi E, Mohammadi M, Moradi T. High risk of cardiovascular diseases after diagnosis of multiple Sclerosis. Mult Scler J. 2013; 19(10):1336-40. [DOI:10.1177/1352458513475833] [PMID] [
DOI:10.1177/1352458513475833]
18. Christiansen CF, Christensen S, Farkas DK, Miret M, Sørensen HT, Pedersen L. Risk of arterial cardiovascular diseases in patients with multiple Sclerosis: A population-based cohort study. Neuroepidemiology. 2010; 35(4):267-74. [DOI:10.1159/000320245] [PMID] [
DOI:10.1159/000320245]
19. Marrie RA, Reider N, Cohen J, Stuve O, Trojano M, Cutter G, et al. A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple Sclerosis. Mult Scler J. 2015; 21(3):318-31. [DOI:10.1177/1352458514564490] [PMID] [PMCID] [
DOI:10.1177/1352458514564490]
20. Tseng CH, Huang WS, Lin CL, Chang YJ. Increased risk of ischemic stroke among patients with multiple Sclerosis. Eur J Neurol. 2015; 22(3):500-6. [DOI:10.1111/ene.12598] [
DOI:10.1111/ene.12598]
21. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet. 2008; 371(9624):1612-23. [DOI:10.1016/S0140-6736(08)60694-7] [
DOI:10.1016/S0140-6736(08)60694-7]
22. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011; 42(2):517-84. [DOI:10.1161/STR.0b013e3181fcb238] [PMID] [
DOI:10.1161/STR.0b013e3181fcb238]
23. The American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2010 update: A report from the American Heart Association. Circulation. 2010; 121(7):e46-e215. [PMID] [
PMID]
24. Harmsen P, Lappas G, Rosengren A, Wilhelmsen L. Long-term risk factors for stroke: Twenty-eight years of follow-up of 7457 middle-aged men in Göteborg, Sweden. Stroke. 2006; 37(7):1663-7. [DOI:10.1161/01.STR.0000226604.10877.fc] [PMID] [
DOI:10.1161/01.STR.0000226604.10877.fc]
25. Haas LF. Stroke as an early manifestation of systemic lupus erythematosus. Journal of Neurology, Neurosurgery & Psychiatry. 1982; 45(6):554-6. [DOI:10.1136/jnnp.45.6.554] [PMID] [PMCID] [
DOI:10.1136/jnnp.45.6.554]
26. Neville C, Rauch J, Kassis J, Solymoss S, Joseph L, Belisle P, et al. Antiphospholipid antibodies predict imminent vascular events independently from other risk factors in a prospective cohort. Thrombosis and Haemostasis. 2009; 101(1):100-7. [DOI:10.1160/TH08-06-0384] [PMID] [PMCID] [
DOI:10.1160/TH08-06-0384]
27. Brey RL, Muscal E, Chapman J. Antiphospholipid antibodies and the brain: A consensus report. Lupus. 2011; 20(2):153-7. [DOI:10.1177/0961203310396748] [PMID] [
DOI:10.1177/0961203310396748]
28. Sebastiani GD, Galeazzi M, Tincani A, Piette JC, Font J, Allegri F, et al. Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Scandinavian Journal of Rheumatology. 1999; 28(6):344-51. [DOI:10.1080/03009749950155320] [PMID] [
DOI:10.1080/03009749950155320]
29. Soltesz P, Veres K, Lakos G, Kiss E, Muszbek L, Szegedi G. Evaluation of clinical and laboratory features of antiphospholipid syndrome: A retrospective study of 637 patients. Lupus. 2003; 12(4):302-7. [DOI:10.1191/0961203303lu339oa] [PMID] [
DOI:10.1191/0961203303lu339oa]
30. Alarc N, Segovia D, Deleze M, Oria CV. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients. Med. 1989; 68(6):353–65. [DOI:10.1097/00005792-198911000-00003] [
DOI:10.1097/00005792-198911000-00003]
31. Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in Systemic Lupus Erythematosus (SLE) and in non SLE disorders. Ann Intern Med. 1990; 112(9):682–98. [DOI:10.7326/0003-4819-112-9-682] [PMID] [
DOI:10.7326/0003-4819-112-9-682]
32. Remondino G, Allevi A. Antiphospholipid antibodies and autoimmune diseases. Open Autoimmun J. 2010; 2:38-44. [DOI:10.2174/1876894601002020038] [
DOI:10.2174/1876894601002020038]
33. Tarr T, Lakos G, Bhattoa HP, Szegedi G, Shoenfeld Y, Kiss E. Primary antiphospholipid syndrome as the forerunner of systemic lupus erythematosus. Lupus. 2007; 16(5):324-9. [DOI:10.1177/0961203307077993] [PMID] [
DOI:10.1177/0961203307077993]
34. Tanasescu R, Nicolau A, Ticmeanu M, Cojocaru I, Ene A, Caraiola S, et al. Headache, antiphospholipid antibodies and cerebral ischemia in patients with systemic immune-mediated diseases. Rom J Neurol. 2007; 6(2):71-108.